NEWS

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

• Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
• Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
• Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

• Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
• CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
• CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
• CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023

Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.

Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.

• CVN766 was well tolerated with no serious adverse events
• CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
• Data supports once a day dosing of CVN766 in future studies

Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.

• Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
• Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
• Data has been concurrently published in the peer-reviewed journal, Neuropharmacology

Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.

‍

Carrie Cook, chief business officer (CBO) of Cerevance, will participate in a fireside chat during the 5^th Annual LSX World Congress USA being held in Boston, MA, June 21-22.

Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.